Loading
NASDAQHealthcareMedical - Devices
Latest quote
$1.50
−$0.06 · -3.85%
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
Latest quote
$1.50
−$0.06 · -3.85%
After-hours
$1.5251
+$0.0251 · +1.67%
Sep 14, 7:30 PM ET
Regular session · ET · Market data may be delayed.
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
Day range
Current $1.50
52-week range
Current $1.50
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
69
Undervalued
Sentiment
30
Bearish
Risk
64
High Risk
Momentum
22
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
Day range
Current $1.50
52-week range
Current $1.50
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 12.1M USD | 3.45M USD | 1.95M USD | 171.17K USD | 178.15K USD |
| Cost of goods sold | 3.96M USD | 2.37M USD | 1.5M USD | 241.96K USD | 275.9K USD |
| Gross profit | 8.14M USD | 1.08M USD | 456.52K USD | −70.79K USD | −97.75K USD |
| Research and development | 4.98M USD | 5.07M USD | 6.94M USD | 4.93M USD | 3.93M USD |
| Selling, general, and administrative | 7.38M USD | 7.9M USD | 6.93M USD | 6.98M USD | 6.26M USD |
| Operating expenses | 12.37M USD | 12.97M USD | 12.41M USD | 9.96M USD | 10.12M USD |
| Interest expense | 334.06K USD | 228.99K USD | — | — | 3.05K USD |
| Depreciation and amortization | 261.68K USD | 246.79K USD | 199.27K USD | 118.62K USD | 147.13K USD |
| Operating income | −4.23M USD | −11.89M USD | −11.96M USD | −10.03M USD | −10.22M USD |
| Net income | −3.61M USD | −12.32M USD | −11.86M USD | −10M USD | −9.95M USD |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$5.00
233.33% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 16, 2026 | 1:6 | — | — |
Stock split | Apr 1, 2021 | 1:3 | — | — |
Effective Apr 16, 2026
1:6
Effective Apr 1, 2021
1:3
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
